Orexo AB

ORX · Nasdaq Stockholm · Healthcare

13.40SEK −2.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −59.5%

Performance

1 month

−13.0%

1 year

−59.5%

3 years, per year

−7.3%

5 years, per year

−16.6%

Largest fall, 3 years

−75.9%

Below the peak now

−92.6%

Volatility, 1 year

60.9%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

1.9

Dividend yield

0.0%

Return on equity

−423.4%

Net margin

−37.1%

Market value

53 m USD

Quality, value and trend

Where Orexo stands against every Nordic stock today. 100 is best.

Quality81

Profitability and a sound balance sheet over time. Better than 81% of Nordic stocks.

Value31

The price measured against earnings, assets and cash flow. Better than 31% of Nordic stocks.

Trend4

The price development over the past year. Better than 4% of Nordic stocks.

Combined27

Quality, value and trend together. Better than 27% of Nordic stocks.

About Orexo

Orexo AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 61 employees.

Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis